Other headlines:Vital Images snags service cert
Pam Pure was to be the headliner at McKesson's Healthcare Information and Management Systems Society 2009 media briefing and luncheon, scheduled for April 6, commenting on how the company's products deliver a positive return on investment. But that message will have to come from others in the company. On March 30, Pure abruptly left McKesson, where she had served as president of Technology Solutions for the past five years. The announcement, made March 31, gave no explanation for her departure but stated that "the deep and experienced management team within McKesson Technology Solutions will continue to lead the businesses in the segment." In the prepared statement, chairman and CEO John H. Hammergren expressed "the sincere thanks of everyone at McKesson for her leadership in building McKesson Technology Solutions into what it is today."
With service assuming increasing importance in the IT industry, Vital Images hopes to make hay as the first advanced medical visualization provider to achieve certification for Excellence in Service Operations by the Service & Support Professionals Association. The certification ranks the company's support operations, customer satisfaction, service sales and marketing, product serviceability, technology infrastructure, and human resource systems in the same league as those of HP, Cisco, and Xerox, which have received similar certifications, according to Vital Images.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.